7 233

Cited 51 times in

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

DC FieldValueLanguage
dc.contributor.author민유홍-
dc.contributor.author정준원-
dc.date.accessioned2014-12-18T09:50:37Z-
dc.date.available2014-12-18T09:50:37Z-
dc.date.issued2013-
dc.identifier.issn0007-1048-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/88934-
dc.description.abstractThe present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44% vs. 52%), OS (26 vs. 22.9 months), EFS (7.7 vs. 7.0 months), and rate of leukaemic transformation (16% vs. 22% at 1 year). In patients ≥ 65 years of age, survival was significantly better in the azacitidine group (P = 0.017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients ≥ 65 years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfBRITISH JOURNAL OF HAEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntimetabolites/adverse effects-
dc.subject.MESHAntimetabolites/therapeutic use*-
dc.subject.MESHAzacitidine/adverse effects-
dc.subject.MESHAzacitidine/analogs & derivatives*-
dc.subject.MESHAzacitidine/therapeutic use*-
dc.subject.MESHBone Marrow Examination-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInfection Control-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHKaryotyping-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMyelodysplastic Syndromes/classification-
dc.subject.MESHMyelodysplastic Syndromes/drug therapy*-
dc.subject.MESHMyelodysplastic Syndromes/genetics-
dc.subject.MESHMyelodysplastic Syndromes/pathology-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHResearch Design-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleComparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorYun-Gyoo Lee-
dc.contributor.googleauthorInho Kim-
dc.contributor.googleauthorSung-Soo Yoon-
dc.contributor.googleauthorSeonyang Park-
dc.contributor.googleauthorJune Won Cheong-
dc.contributor.googleauthorYoo Hong Min-
dc.contributor.googleauthorJeong-Ok Lee-
dc.contributor.googleauthorSoo-Mee Bang-
dc.contributor.googleauthorHyeon Gyu Yi-
dc.contributor.googleauthorChul Soo Kim-
dc.contributor.googleauthorYong Park-
dc.contributor.googleauthorByung-Soo Kim-
dc.contributor.googleauthorYeung-Chul Mun-
dc.contributor.googleauthorChu-Myoung Seong-
dc.contributor.googleauthorJinny Park-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorSung-Yong Kim-
dc.contributor.googleauthorHong Ghi Lee-
dc.contributor.googleauthorYeo-Kyeoung Kim-
dc.contributor.googleauthorHyeoung-Joon Kim-
dc.identifier.doi10.1111/bjh.12256-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01407-
dc.contributor.localIdA03729-
dc.relation.journalcodeJ00409-
dc.identifier.eissn1365-2141-
dc.identifier.pmid23432512-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/bjh.12256/abstract-
dc.subject.keywordAdolescent-
dc.subject.keywordAdult-
dc.subject.keywordAged-
dc.subject.keywordAged, 80 and over-
dc.subject.keywordAntimetabolites/adverse effects-
dc.subject.keywordAntimetabolites/therapeutic use*-
dc.subject.keywordAzacitidine/adverse effects-
dc.subject.keywordAzacitidine/analogs & derivatives*-
dc.subject.keywordAzacitidine/therapeutic use*-
dc.subject.keywordBone Marrow Examination-
dc.subject.keywordDisease-Free Survival-
dc.subject.keywordFemale-
dc.subject.keywordHumans-
dc.subject.keywordInfection Control-
dc.subject.keywordKaplan-Meier Estimate-
dc.subject.keywordKaryotyping-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordMyelodysplastic Syndromes/classification-
dc.subject.keywordMyelodysplastic Syndromes/drug therapy*-
dc.subject.keywordMyelodysplastic Syndromes/genetics-
dc.subject.keywordMyelodysplastic Syndromes/pathology-
dc.subject.keywordNeutropenia/chemically induced-
dc.subject.keywordResearch Design-
dc.subject.keywordRetrospective Studies-
dc.subject.keywordRisk Assessment-
dc.subject.keywordTreatment Outcome-
dc.subject.keywordYoung Adult-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.rights.accessRightsnot free-
dc.citation.volume161-
dc.citation.number3-
dc.citation.startPage339-
dc.citation.endPage347-
dc.identifier.bibliographicCitationBRITISH JOURNAL OF HAEMATOLOGY, Vol.161(3) : 339-347, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.